AntiVEGFhoidossa

AntiVEGFhoidossa refers to treatment using anti-VEGF medications. VEGF stands for Vascular Endothelial Growth Factor, a protein that plays a crucial role in the formation of new blood vessels, a process known as angiogenesis. In certain diseases, particularly those affecting the eyes, excessive production of VEGF can lead to abnormal and leaky blood vessel growth. These abnormal vessels can cause significant vision loss.

Anti-VEGF medications work by blocking the action of VEGF. By inhibiting VEGF, these drugs prevent the formation of new, abnormal blood vessels and can also reduce leakage from existing ones. This therapeutic approach is primarily used in ophthalmology to treat conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusions. These conditions can all lead to severe and irreversible vision impairment if left untreated.

The administration of anti-VEGF medications in the eye is typically done through intravitreal injections, meaning the drug is injected directly into the vitreous humor, the gel-like substance filling the eyeball. This method ensures the medication reaches the intended site of action effectively. The frequency of injections varies depending on the specific condition and the patient's response to treatment, often requiring regular follow-up appointments and monitoring by an ophthalmologist. While generally well-tolerated, potential side effects can include eye inflammation, pain, or a slight increase in intraocular pressure.